U.S. Sucralfate Market – Market Insights
Sucralfate is the generic form of the brand-name drug, Carafate. It is a prescription medicine used to treat ulcers of the upper gastrointestinal tract, peptic ulcer disease, and to prevent reoccurrence of ulcers.
The U.S. sucralfate market size was valued at US$ 296.2 million in 2017, and is expected to exhibit a CAGR of 3.1% over the forecast period (2018–2026).
Figure 1. U.S. Sucralfate Market Value (US$ Mn), by Distribution Channel, 2018
Market Value (US$ Mn),
Source: Coherent Market Insights Analysis (2019)
Increasing prevalence of gastrointestinal disorders and H. pylori-associated infections is expected to propel the market growth
Rising incidence of gastric ulcers caused due to use of nonsteroidal anti-Inflammatory drugs (NSAID) and H. pylori infection is expected to drive the U.S. sucralfate market. According to the study by Deccan College of Medical Sciences, 2016, an estimated 95% of duodenal and 70% of gastric ulcers are caused due to Helicobacter pylori. Furthermore, the same study also stated that around 14-25% of gastric and duodenal ulcers are associated with NSAID use.
Rising prevalence of peptic ulcers is expected to bolster the market growth. According to the data published by ScienceDirect Journal in 2016, duodenal ulcers are more common type of peptic ulcers and its prevalence was around 6% to 12% in the U.S.
Figure 2. U.S. Sucralfate Market Share (%), by Distribution Channel, 2018 and 2026
Source: Coherent Market Insights Analysis (2019)
Increasing collaboration and acquisition strategies adopted by market players is expected to bolster the market growth
The U.S. sucralfate market is expected to witness significant growth, owing to increasing inorganic growth strategies such as collaboration and acquisitions by market players. For instance, in 2014, Aptalis Pharma Inc., a specialty pharmaceutical company and manufacturer of Carafate, was acquired by Forest Laboratories, Inc., a fully integrated, specialty pharmaceutical company. Forest agreed to acquire Aptalis from TPG, the global private investment firm, for US$ 2.9 billion in cash.
Increasing applications and uses of sucralfate in the U.S. is expected to drive the market growth. According to the American Broncho Esophagological Association report, in April 2018, use of sucralfate along with honey aids in treatment of esophageal injury in infants and children. Esophageal injury in infants and children are associated with consumption of Button Batteries (BB), small disc-shaped batteries commonly found in toys.
Moreover, increasing prevalence of gastro-esophageal reflux disease (GERD) and Helicobacter pylori infection is expected to bolster the U.S. sucralfate market over the forecast period. For instance, according to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the prevalence of GERD was reported in the range from 15% to 30% in the U.S. in 2014. Similarly, according to the data published in American Gastroenterological Association (AGA) Journal in 2017, the prevalence of Helicobacter pylori positive infection is 35.6% among the population in the U.S.
Major players operating in the U.S. sucralfate market include Teva Pharmaceutical Industries Ltd., Allergan plc, Vertice Pharma LLC, and Pharmaceutical Associates Inc.
Sucralfate is a hydroxy aluminum salt of sucrose octasulfate that functions as a local mucosal adherent. It forms a coating over ulcers by sticking to the affected area, which protects the area from acid and enzymes and helps ulcers to heal more quickly. Sucralfate can also be used in treating ulcers and upper gastrointestinal disorders of dog, horse, and cat, which may arise due to drugs (particularly non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids), toxic chemical ingestion, liver disease, renal failure, carcinoma, stress (trauma, shock, sepsis, and burns), and inflammatory bowel disease.
Increasing clinical trials for exploring different uses of sucralfate for different indications is a major factor driving U.S. sucralfate market growth. For instance, according to the study published by the National Center of Biotechnology Information, in 2016, a clinical trial conducted on Radiation Proctitis patients receiving sucralfate treatment showed 92.3% positive results in 16 weeks.
Furthermore, monitoring of drugs including sucralfate in the U.S. by the government authorities for avoiding fatal conditions in the population is expected to drive the market growth. For instance, in 2017, the U.S. FDA updated name of 'Carafate suspension' to 'Carafate oral suspension' to avoid fatal complications with mistakenly intravenous administration of the drug.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.